Asset

Carfilzomib

Amgen Inc. Common Stock

Revenue

PeriodRevenue
Q2 2026$314.0M
Q1 2026$330.0M
Q3 2025$359.0M
Q2 2025$378.0M
Q1 2025$324.0M
Q4 2024$372.0M
Q3 2024$378.0M
Q2 2024$377.0M
Q1 2024$376.0M
Q4 2023$350.0M
Q3 2023$349.0M
Q2 2023$346.0M
Q1 2023$358.0M
Q4 2022$325.0M
Q3 2022$318.0M

Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.

Clinical trials (24)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT01980589phase1completed2013-08-012016-03-01AmgenA Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
NCT03859427phase3completed2019-05-082023-03-31AmgenA Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03512353phase2terminated2018-07-052020-01-16AmgenA Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
NCT01302392phase3completed2010-09-012014-07-01AmgenA Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
NCT00884312phase2completed2009-04-092017-05-17AmgenA Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

FDA applications (1)

ApplicationTypeApplicant
NDA 202714NDAONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC

Marketed products (3)

  • KYPROLIS
  • KYPROLIS
  • KYPROLIS